Skip to content
20-F

Annual Report (Foreign)

Chemomab Therapeutics Ltd. CMMB

0001178913-26-001593

← back to feed
Filed
Mar 23, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 510.23M sh
Shares Diluted FY 2025 · Dec 31, 2024 359.05M sh
Shares Diluted FY 2025 · Dec 31, 2023 235M sh
Shares Outstanding FY 2025 · Dec 31, 2025 575.38M sh
Capex FY 2025 · Dec 31, 2025 $3K
Capex FY 2025 · Dec 31, 2024 $0
Capex FY 2025 · Dec 31, 2023 $3K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$11.13M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$15.39M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$23.61M
Cash And Equivalents FY 2025 · Dec 31, 2025 $7.56M
Cash And Equivalents FY 2025 · Dec 31, 2024 $6.07M
Stockholders Equity FY 2025 · Dec 31, 2025 $12.33M
Stockholders Equity FY 2025 · Dec 31, 2024 $13.54M
Stockholders Equity FY 2025 · Dec 31, 2023 $17M
Stockholders Equity FY 2025 · Dec 31, 2022 $36.22M
Current Liabilities FY 2025 · Dec 31, 2025 $1.48M
Current Liabilities FY 2025 · Dec 31, 2024 $3.22M
Total Liabilities FY 2025 · Dec 31, 2025 $1.48M
Total Liabilities FY 2025 · Dec 31, 2024 $3.43M
Current Assets FY 2025 · Dec 31, 2025 $13.43M
Current Assets FY 2025 · Dec 31, 2024 $16.04M
Total Assets FY 2025 · Dec 31, 2025 $13.81M
Total Assets FY 2025 · Dec 31, 2024 $16.96M
Eps Diluted FY 2025 · Dec 31, 2025 $0.02
Eps Diluted FY 2025 · Dec 31, 2024 $0.04
Eps Diluted FY 2025 · Dec 31, 2023 $0.10
Eps Basic FY 2025 · Dec 31, 2025 $0.02
Eps Basic FY 2025 · Dec 31, 2024 $0.04
Eps Basic FY 2025 · Dec 31, 2023 $0.10
Sga Expense FY 2025 · Dec 31, 2025 $3.73M
Sga Expense FY 2025 · Dec 31, 2024 $3.41M
Sga Expense FY 2025 · Dec 31, 2023 $7.08M
Rd Expense FY 2025 · Dec 31, 2025 $5.83M
Rd Expense FY 2025 · Dec 31, 2024 $11.33M
Rd Expense FY 2025 · Dec 31, 2023 $18.38M
Net Income FY 2025 · Dec 31, 2025 −$9M
Net Income FY 2025 · Dec 31, 2024 −$13.95M
Net Income FY 2025 · Dec 31, 2023 −$24.22M
Operating Income FY 2025 · Dec 31, 2025 −$112M
Cost Of Revenue FY 2025 · Dec 31, 2025 $2.33M
Cost Of Revenue FY 2025 · Dec 31, 2024 $2.47M
Cost Of Revenue FY 2025 · Dec 31, 2023 $4.39M